UK markets closed

Inventiva S.A. (IVEVF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.95000.0000 (0.00%)
At close: 01:18PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.9500
Open4.9500
BidN/A x N/A
AskN/A x N/A
Day's range4.9500 - 4.9500
52-week range4.1000 - 13.6400
Volume1,500
Avg. volume206
Market cap241.055M
Beta (5Y monthly)1.30
PE ratio (TTM)N/A
EPS (TTM)-1.3330
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est23.55
  • Globe Newswire

    Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

    New patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage This patent strengthens and expands the intellectual property protection of lanifibranor in the United States particularly for use for patients with cirrhotic NASH Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Compa

  • Globe Newswire

    Inventiva announces a new Director of the Board of Directors

    Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announces that, effective on November 9th, 2022, Inventiva’s board of directors coopted Dr. Lucy Lu as the Director of its Board of Directors in lieu of S

  • Globe Newswire

    Inventiva reports 2022 Third Quarter Financial Information¹

    Cash position2 at €72.6m as of September 30, 2022, not including the $12.6 million upfront payment received from Sino Biopharm on November 4, 2022Revenues of €0.1m for the first nine months of 2022 Daix (France), Long Island City (New York, United States), November 10, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepat